Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telemedicine for MOUD, PrEP, and HCV at Needle Exchanges
NCT05108935Completed
- Sponsor
- Duke University
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of Suboxone, emtricitabine + tenofovir disoproxil and glecaprevir in opioid use disorder (OUD), human immunodeficiency virus infection (HIV) and hepatitis C (HCV), sponsored by Duke University. Primary endpoints: Proportion who demonstrate no or minimal opioid use at 6 months, Proportion who remain HIV negative at 6 months and 9 more. Started Feb 2022; status: completed.
02
Drugs
Suboxoneemtricitabine + tenofovir disoproxilglecaprevir
03
Conditions
opioid use disorder (OUD)human immunodeficiency virus infection (HIV)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05108935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108935.